Back to Research & Science
Research & Science•••9 min read

CJC-1295 With DAC vs Without DAC

CJC-1295 with DAC vs without DAC (Mod GRF 1-29): what DAC means, half-life evidence, what human studies measured, and FDA and WADA status in 2026.

PeptIQ Team
Peptide Research & Education
CJC-1295 With DAC vs No DAC: What's the Difference?

PeptIQ app

Log your CJC-1295 protocol in PeptIQ

Turn this CJC-1295 guide into a living protocol — doses, vials, and history in one place.

Track CJC-1295Open web app

iOS, Android, and web

Ask PeptIQ

Two taps on our guided quiz, then keep going in iMessage with sources — not Instagram screenshots.

Start the quizOr try Peptide X Quiz →

TL;DR

"CJC-1295 with DAC" and "CJC-1295 without DAC" are two different molecules that share a name. Both are lab-made versions of a fragment of growth hormone-releasing hormone (GHRH). The DAC version carries an extra chemical linker that lets it attach to albumin in the blood, which is why it lasts for days. The no-DAC version, often sold as "Mod GRF 1-29," lacks that linker and is short-acting.

The published human evidence belongs almost entirely to the DAC version: two small 2006 trials in healthy adults that measured hormone levels, plus one hormone-pattern study. Those trials did not measure muscle, fat loss, recovery or longevity. We could not find a peer-reviewed human trial of the no-DAC version under that name. Neither form is an FDA-approved medicine, and both fall under the growth hormone-releasing factors that WADA prohibits at all times.

This PeptIQ.io guide explains the difference, what was measured, and what to ask a clinician. It contains no dosing information. Updated November 2, 2026.

Talk to a licensed clinician before starting, stopping or changing anything that affects your hormones.

What Is CJC-1295?

Your hypothalamus releases GHRH, which signals the pituitary gland to release growth hormone (GH). GH in turn raises insulin-like growth factor 1 (IGF-1), mostly from the liver. Natural GHRH is broken down within minutes, which is the main reason it has been hard to use as a drug. The 2006 human pharmacokinetic study of CJC-1295 opens with exactly that problem: GHRH's usefulness "is limited by its short duration of action."

Researchers at the Canadian company ConjuChem tried to fix that. Their 2005 rat study describes CJC-1295 as a tetrasubstituted form of hGRF(1-29). That means the first 29 amino acids of human GHRH, with four amino acids swapped to resist enzyme breakdown, plus a reactive maleimide group added to a lysine at the end. That reactive group is the "DAC," short for Drug Affinity Complex.

What Does DAC Mean?

DAC is the reactive add-on that lets the peptide bind to albumin, the most abundant protein in blood. In the rat study, the maleimide group linked to a specific site on albumin (the free thiol on Cys34). The bound peptide showed up on the albumin band of a Western blot 15 minutes after injection and was still circulating more than 24 hours later. CJC-1295 itself was detectable in plasma beyond 72 hours.

Once the peptide rides on albumin, it is protected from rapid clearance. In healthy adults, the estimated half-life of CJC-1295 with DAC was 5.8 to 8.1 days (Teichman et al., 2006).

"Without DAC" refers to the same tetrasubstituted GRF(1-29) backbone without the albumin-binding group. Online sellers often call it "Mod GRF 1-29" or "modified GRF 1-29." Without the linker, nothing anchors it to albumin, so it is expected to clear far faster. We did not find a published human pharmacokinetic study of the no-DAC form, so we are not giving it a half-life number here. Figures quoted in forums are not the same as measured trial data.

PeptIQ.io / CJC-1295 / 01

One backbone. One added linker.

Both products start from GHRH's first 29 amino acids, with four swapped to resist breakdown. Only one carries the Drug Affinity Complex.

Without DAC

“Mod GRF 1-29”

Not measured

No published human half-life. Same modified backbone, with nothing anchoring it in the blood.

With DAC

CJC-1295 (ConjuChem)

5.8–8.1 days

Estimated half-life in healthy adults after the linker binds albumin.

A label reading only “CJC-1295” does not tell you which molecule is inside.

Measured, not marketed.Nov 2026
Schematic, not to scale; dots do not mark substitution positions. Sources: Jetté et al., Endocrinology 2005; Teichman et al., J Clin Endocrinol Metab 2006. No dosing information.

CJC-1295 DAC vs No DAC: Side-by-Side

QuestionCJC-1295 with DACCJC-1295 without DAC ("Mod GRF 1-29")
BackboneTetrasubstituted GRF(1-29)Same tetrasubstituted GRF(1-29)
Albumin-binding linkerYes (maleimide "DAC")No
Measured human half-life5.8–8.1 days (healthy adults, 2006)No peer-reviewed human measurement found
Published human trialsTwo randomized placebo-controlled trials plus one GH-pattern studyNone found under this name
What studies measuredGH and IGF-1 levelsNot studied in published human trials
FDA statusNot approved; FDA lists safety concernsNot approved
WADA statusProhibited at all times (S2.2.4)Covered as a GHRH analogue (S2.2.4)

A label that says only "CJC-1295" does not tell you which molecule is inside. That ambiguity matters for any conversation with a clinician and for reading testing paperwork such as a certificate of analysis.

What the Human Evidence Actually Shows

The 2006 pharmacokinetic trials (DAC)

Teichman and colleagues ran two randomized, placebo-controlled, double-blind, ascending-dose trials lasting 28 and 49 days. Participants were healthy adults aged 21 to 61, studied at two sites.

After a single injection, mean GH concentrations rose 2- to 10-fold for six days or more, and mean IGF-1 rose 1.5- to 3-fold for 9 to 11 days, depending on dose. After repeated doses, mean IGF-1 stayed above baseline for up to 28 days. The authors reported no serious adverse reactions and described the drug as "relatively well tolerated."

What those trials did not measure: muscle size, strength, body fat, sleep, injury recovery, skin or longevity. They were short, small and run by people connected to the developer. They answered a pharmacology question, not a "does it work for my goal?" question.

The GH pulsatility study (DAC)

GH is normally released in pulses, mostly overnight. A follow-up study by Ionescu and Frohman sampled blood every 20 minutes overnight in healthy men aged 20 to 40, before and one week after a single CJC-1295 injection.

Pulse frequency and size were unchanged. What changed was the floor: trough GH rose about 7.5-fold, mean GH rose 46% and IGF-1 rose 45%. In other words, the long-acting version raised baseline GH between pulses rather than creating bigger pulses. That contradicts a common online claim that only the no-DAC form preserves a "natural" pulse pattern. The DAC version kept pulses in this study. What it added was a higher, continuous baseline. Whether that matters for health outcomes was not tested.

The phase 2 trial that stopped

ConjuChem registered a phase 2 trial of CJC-1295 in people with HIV-associated visceral obesity (NCT00267527), started December 2005. The registry lists it as terminated, last updated in October 2006, with no results posted and no reason given. We are not speculating about why it stopped. It means the one registered efficacy trial never produced public efficacy data.

What about the no-DAC version?

Our PubMed searches for "modified GRF (1-29)," "mod GRF 1-29" and "tetrasubstituted GRF" returned no human clinical trials of the no-DAC molecule. A 2026 review in Frontiers in Endocrinology lists CJC-1295 with and without DAC among peptides marketed as "research compounds." It notes uncertainty about product composition in unregulated supply chains and sorts these peptides into evidence tiers, from randomized trial data down to a complete absence of human studies.

PeptIQ.io / CJC-1295 / 02

What was measured, and what wasn’t.

Almost all human data belong to the DAC version, and all of it describes hormone levels rather than the outcomes people search for.

  1. 01

    Lab & animal

    Jetté et al., 2005

    Linker binds albumin in rats; peptide detectable beyond 72 hours.

  2. 02

    Human pharmacology

    Teichman et al., 2006

    Two short placebo-controlled trials: GH and IGF-1 rose for days.

  3. 03

    Human GH pattern

    Ionescu & Frohman, 2006

    Pulses unchanged; trough GH about 7.5-fold higher.

  4. 04

    Efficacy trial

    NCT00267527

    Phase 2 in HIV-associated visceral obesity terminated; no results posted.

  5. 05

    Muscle, fat, recovery

    Not studied

    No published human trial measured these outcomes for either form.

Measured, not marketed.Nov 2026
Evidence ladder for CJC-1295 with DAC. No peer-reviewed human trial of the no-DAC form was found in PubMed searches (November 2026). Primary sources linked in the article.

Regulatory Status in 2026

FDA. CJC-1295 is not an FDA-approved drug in either form. FDA's page on bulk drug substances that may present significant safety risks (content current as of April 22, 2026) lists CJC-1295 among nominated-then-withdrawn substances. It says compounded CJC-1295 may pose a risk of immunogenicity for certain routes, has complexities around peptide-related impurities, and that FDA "has identified serious adverse events" including increased heart rate and a systemic vasodilatory reaction. It adds that "available clinical data are limited."

HHS, October 2026. HHS announced an interim enforcement-discretion policy for 503A compounding of certain peptide bulk substances, scheduled for Federal Register publication on October 30, 2026. It applies only to peptides named in the policy's appendix. Do not assume any peptide is included. Ask the dispensing pharmacist or your clinician to confirm current status. For context, see our HHS 503A peptide policy explainer.

Sport. The WADA 2026 Prohibited List names CJC-1295 as an example under S2.2.4, growth hormone-releasing factors, in the section of substances prohibited at all times. "Without DAC" is still a GHRH analogue. Tested athletes should treat both forms as prohibited.

"Research use only." A research-only label is not a medical approval. It means the product has not been through FDA review for human use. Our guide on how to vet a peptide source explains what paperwork can and cannot tell you.

PeptIQ.io / CJC-1295 / 03

Where CJC-1295 stands in 2026.

Neither form is an approved medicine. Rules differ by agency, and they change, so verify before relying on any summary.

FDA

Not approved

Safety-risk page cites immunogenicity, impurities, increased heart rate and a vasodilatory reaction. Clinical data “limited.”

WADA 2026

Banned in sport

Prohibited at all times under S2.2.4 growth hormone-releasing factors. GHRH analogues without DAC are covered too.

HHS 503A policy

Check the list

October 2026 enforcement discretion applies only to listed peptides. Confirm current status with a pharmacist.

“Research use only” is a label, not an approval for human use.

Measured, not marketed.Nov 2026
Sources: FDA bulk drug substances safety-risk page (content current as of April 22, 2026); WADA 2026 Prohibited List; Federal Register 2026-22192. Educational summary, not legal advice.

Safety Questions to Raise With a Clinician

Raising GH and IGF-1 is a hormonal intervention, not a supplement. Short trials in healthy adults cannot tell you about long-term effects. Questions worth bringing to a licensed clinician include:

  • Do I have a medical reason to change GH or IGF-1 at all? An approved GHRH analogue, tesamorelin, exists for a specific indication, and it was studied for that use, not for general wellness.
  • What do my current labs show? A clinician can decide whether IGF-1, glucose or other markers are relevant to you.
  • How does this interact with my conditions and medicines? Diabetes, cancer history, pregnancy, heart rhythm problems and other medicines all change the risk picture.
  • What about the serious adverse events FDA lists? Ask how increased heart rate or a vasodilatory reaction would be recognized and handled.
  • What exactly is in the product? "CJC-1295" alone does not say whether it has DAC, and RUO products are not reviewed for identity, purity or sterility.
  • Am I subject to anti-doping rules? If so, both forms are prohibited.

The 2026 review mentioned above lists adverse effects reported across GH-axis peptides: prolactin and cortisol elevations, appetite changes, blood-sugar disturbances, fluid retention, muscle and joint aches, and injection-site reactions. That review covers a class of compounds, so do not read it as proof that any one of these effects comes from CJC-1295 specifically.

How PeptIQ.io Helps

PeptIQ.io is an education and tracking platform, not a pharmacy or prescriber. If your clinician prescribes a treatment, the PeptIQ.io app lets you keep injection days, sites, symptoms and lab dates on one timeline you can share with your care team. PeptIQ AI can help you turn a study abstract into questions for an appointment. It cannot tell you whether a peptide is right for you. The glossary explains terms like GHRH, IGF-1 and DAC in plain language. For timing concepts, see peptide half-life in plain language.

Talk to a Licensed Clinician

Talk to a licensed clinician before using any growth hormone-releasing peptide. Bring this guide's three key facts: the two CJC-1295 products are different molecules; the human data are short hormone-level studies of the DAC version; and FDA has flagged safety concerns. Ask what your own history and labs mean for that picture. No article can make that decision for you.

Frequently Asked Questions

Q: What is the difference between CJC-1295 with DAC and without DAC?

A: Both share a modified GRF(1-29) backbone. The DAC version carries a reactive linker that binds albumin in the blood, giving it an estimated half-life of about six to eight days in healthy adults. The no-DAC version ("Mod GRF 1-29") lacks the linker and is short-acting.

Q: Is Mod GRF 1-29 the same as CJC-1295?

A: "Mod GRF 1-29" is usually used for CJC-1295 without DAC. Labels are inconsistent, so a product called "CJC-1295" may be either form. Only the documentation can tell you which.

Q: Which version has more human research?

A: The DAC version. Two randomized placebo-controlled trials and one pulsatility study in healthy adults were published in 2006. We found no peer-reviewed human trial of the no-DAC form.

Q: Does CJC-1295 build muscle or burn fat?

A: That has not been shown. The published human trials measured GH and IGF-1 levels over weeks, not muscle, strength or fat. Hormone changes are not the same as body-composition results.

Q: Is CJC-1295 FDA approved or legal?

A: It is not FDA approved in either form. FDA lists safety concerns about compounded CJC-1295, and WADA prohibits it at all times for athletes. Rules on sale and compounding can change, so check current status with a pharmacist or clinician.

Q: Does the DAC version stop natural GH pulses?

A: Not in the one study that checked. Pulse frequency and size were unchanged a week after a single injection, while baseline (trough) GH rose markedly.

Related Guides

Sources

This article is educational content from PeptIQ.io. It is not medical advice. Talk with a licensed clinician before starting, stopping, or changing any peptide, medication, or injection practice.

For clinics: running peptide or GLP-1 programs for patients? See PeptIQ.io for providers: protocol templates, a patient app, and adherence tracking in one console.

Share this article

Track Your Peptide Protocols

Use PeptIQ to log injections and vial supply, use peptiq.io calculators for math on the web, and keep protocols organized.

Stay ahead of the peptide conversation

Weekly-ish notes on new research, wiki trends, and practical tracking tips. No spam — unsubscribe anytime.

Educational updates only — not medical advice. Privacy